Abstract:Acute kidney injury leading to chronic kidney disease through tubulointerstitial fibrosis is a major challenge in nephropathy. Several signaling pathways promote interstitial fibrosis; however, effective suppression of fibrosis may require blockade of more than one pathway. This study investigated whether blockade of Smad3 and c-Jun N-terminal kinase (JNK) signaling gives added suppression of interstitial fibrosis in folic acid nephropathy. A single high dose of folic acid (FA) causes acute tubular damage in C57BL/6J mice followed by interstitial fibrosis and chronic renal impairment. Co-activations of Smad3 and JNK signaling occur in both tubular epithelial cells and myofibroblasts in areas of tubulointerstitial damage and fibrosis in both murine FA-induced nephropathy and human IgA nephropathy. Groups of mice were treated with a Smad3 inhibitor (SIS3), a JNK inhibitor (SP600125), or a combination from day 6 after FA administration until being killed on day 28. Each drug efficiently inhibited its specific target (Smad3 phosphorylation or c-Jun phosphorylation) without affecting the other pathway. Given alone, each drug partially reduced renal fibrosis, whereas the combination therapy gave an additive and profound protection from renal fibrosis and improved renal function. Inhibition of Smad3 and/or JNK signaling activities prevented down-regulation of PGC-1α in tubular epithelial cells and up-regulation of PGC-1α in myofibroblasts during FA-induced renal fibrosis and inflammation. The expression of PGC-1α was upregulated in Smad3 -/- NRK52E cells while downregulated in Smad3 -/- NRK49F cells, suggesting that Smad3 signaling may regulate expression of PGC-1α in renal tubular epithelial cells and fibroblasts in distinct fashion. In vivo and cell culture studies also indicate that Smad3 and JNK signaling cooperate to cause mitochondrial dysfunction and cell damage in tubular epithelial cells via direct actions on the transcription of PGC-1α. These pathways also act cooperatively to promote renal fibroblast proliferation in tempo-spatial fashion. In conclusion, we have identified a potential combination therapy for progressive renal fibrosis which operates, in part, through modifying mitochondrial function.

Pharmacological Inhibition of S100A4 Attenuates Fibroblast Activation and Renal Fibrosis

Smad7 Inhibits Fibrotic Effect of TGF- on Renal Tubular Epithelial Cells by Blocking Smad2 Activation

Mir-192 Mediates TGF-beta/Smad3-driven Renal Fibrosis.

Pharmacological Inhibition of STING/TBK1 Signaling Attenuates Myeloid Fibroblast Activation and Macrophage to Myofibroblast Transition in Renal Fibrosis

TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29.

renal interstitial fi brosis in obstructive nephropathy by interfering TGF-b 1 / Smad 3 signaling †

Combined Blockade of Smad3 and JNK Pathways Ameliorates Progressive Fibrosis in Folic Acid Nephropathy

MicroRNA-140-5p Mediates Renal Fibrosis Through TGF-β1/Smad Signaling Pathway by Directly Targeting TGFBR1

Downregulation of S100A4 Alleviates Cardiac Fibrosis Via Wnt/β -Catenin Pathway in Mice.

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

The Role and Mechanism of TGF-β1-mediated Smad Pathway in Renal Fibrosis

New Insights into TGF-β/Smad Signaling in Tissue Fibrosis.

A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.

Activation Of Sirtuin-1 Promotes Renal Fibroblast Activation And Aggravates Renal Fibrogenesis

Nuclear Translocation of SIRT4 Mediates Deacetylation of U2AF2 to Modulate Renal Fibrosis Through Alternative Splicing-mediated Upregulation of CCN2

Pharmacological Inhibition of STAT6 Ameliorates Myeloid Fibroblast Activation and Alternative Macrophage Polarization in Renal Fibrosis

SKLB023 Hinders Renal Interstitial Fibrosis in Obstructive Nephropathy by Interfering TGF-β1/Smad3 Signaling

Regulation of Renal Fibrosis by Smad3 Thr388 Phosphorylation

Sphingosine Kinase 2 Cooperating with Fyn Promotes Kidney Fibroblast Activation and Fibrosis Via STAT3 and AKT.

Inhibition of S100A8/A9 ameliorates renal interstitial fibrosis in diabetic nephropathy.

Inhibition of S100A8/A9 Ameliorates Renal Interstitial Fibrosis in Diabetic Nephropathy